- Home
- MOH vs ARWR Comparison
MOH vs ARWR Comparison
Compare MOH & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOH | ARWR |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.0B |
| IPO Year | 2002 | 2009 |
Fundamental Metrics
Financial Performance| Metric | MOH | ARWR |
|---|---|---|
| Price | $133.21 | $62.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $157.15 | $81.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.0M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 8.92 | 0.22 |
| Revenue | ★ $45,426,000,000.00 | $16,142,321.00 |
| Revenue This Year | $2.30 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | ★ $14.94 | $284.77 |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $121.06 | $10.66 |
| 52 Week High | $359.97 | $76.76 |
Technical Indicators
Market Signals| Indicator | MOH | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 56.75 |
| Support Level | $133.40 | $60.60 |
| Resistance Level | $152.27 | $66.37 |
| Average True Range (ATR) | 6.24 | 3.10 |
| MACD | -0.63 | 0.62 |
| Stochastic Oscillator | 11.30 | 94.65 |
Price Performance
Historical ComparisonAbout MOH Molina Healthcare Inc
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.